Related Experiment Video

Updated: Aug 21, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Beta blocker therapy in African American patients with heart failure

Sidney Goldstein1

  • 1Henry Ford Hospital, 2799 West grand Blvd, Detroit, Michigan 48202, USA. sgoldst1@hfhs.org

Heart Failure Reviews
|November 2, 2004
PubMed

Insights

Beta blocker therapy for heart failure shows similar benefits for African Americans and Caucasians. However, the Beta Blocker Evaluation of Survival Trial (BEST) indicated potential differential effects in African Americans, possibly due to disease severity.

Area of Science:

  • Cardiology
  • Pharmacology
  • Clinical Trials

Background:

  • Beta blocker therapy is a cornerstone treatment for heart failure.
  • Previous clinical trials often had limited representation of African American patients.
  • African Americans with heart failure frequently present with comorbidities like hypertension and diabetes.

Purpose of the Study:

  • To evaluate the efficacy and safety of beta blockers in African Americans with heart failure.
  • To compare treatment outcomes between African American and Caucasian patients.
  • To investigate potential differential responses to beta blocker therapy in specific populations.

Main Methods:

  • Analysis of data from multiple clinical trials on beta blocker therapy for heart failure.
  • Inclusion of data from the Beta Blocker Evaluation of Survival Trial (BEST) focusing on Bucindolol.
  • Stratification of results based on race (African American vs. Caucasian) and comorbidities.

Main Results:

  • Overall, beta blocker therapy demonstrated comparable benefits in African American and Caucasian heart failure patients.
  • African American participants in trials often had higher baseline risks, including hypertension and diabetes.
  • The BEST trial revealed a potential unique differential effect of Bucindolol in African Americans compared to Caucasians, possibly linked to disease severity.

Conclusions:

  • Beta blockers are generally effective for heart failure in African Americans, similar to Caucasians.
  • Underlying health conditions may influence treatment response in specific populations.
  • Further research is warranted to understand differential effects and optimize therapy for diverse patient groups.

Related Concept Videos

Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...